长春高新(000661.SZ)：子公司替勃龙片在境内获批上市

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Drug Registration Certificate approved by the National Medical Products Administration, allowing the launch of Tibralon Tablets in the domestic market [1] Company Summary - Jinsai Pharmaceutical has developed Tibralon Tablets, which are classified as a selective estrogen receptor modulator, specifically designed to treat low estrogen symptoms caused by natural or surgical menopause in women [1] - Tibralon Tablets are categorized as a Class 4 oral chemical drug [1]